Navigation Links
Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy
Date:4/23/2010

ATLANTA and STOCKHOLM, April 23 /PRNewswire/ -- Prof. Lars Leksell (1907-1986), inventor of the radiosurgical instrument that bears his name and a faculty member of Karolinska University Hospital (Solna, Sweden), performed the world's first Gamma Knife® surgery at nearby Sophiahemmet Hospital, the location of the first Leksell Gamma Knife. Karolinska University Hospital recently acquired Elekta's fifth generation radiosurgery system, Leksell Gamma Knife® Perfexion™. Since January, Karolinska clinicians have been using the system to treat more patients per day and tumors that used to be hard to reach. Physicians also are much more easily treating multiple metastases in a single session.

While Karolinska clinicians are currently treating traditional Gamma Knife indications (metastases, meningiomas, arteriovenous malformations, dural fistulas, acoustic neuromas), the immediate impact Perfexion has made is the ease with which physicians can treat two or more metastases in one session.

"We treat five to 10 metastases on a regular basis, because the automated collimator makes it possible to rapidly plan and treat multiple tumor isocenters," Karolinska neurosurgeon Dr. Ernest Dodoo explains. "Suddenly, it is feasible to treat everything we see. Now, the question is not 'Is it technically possible?' but rather 'Does it make sense clinically from a therapy standpoint?'"

Perfexion improves radiosurgery workflow

Leksell Gamma Knife Perfexion replaced two earlier generation Leksell Gamma Knife® 4C systems, one at Sophiahemmet Hospital and the other at Karolinska University Hospital. Each had been treating about 250 patients per year for the last three years. Since the late 1960s, Karolinska has used Gamma Knife surgery for approximately 10,000 patients, according Dr. Dodoo.

On January 11, Karolinska used Leksell Gamma Knife Perfexion to treat its first case, a patient with a glioblastoma. Since then, Karolinska has treated 120 patients with Perfexion and this single system already rivals the daily patient volume of the previous systems by virtue of its unique features. "We treated five patients in one day last week, including two quite complex cases," he recalls. "With either of our previous systems that would have been logistically difficult. With Perfexion, up to five patients per day is absolutely realistic."

In addition to the system's automated collimator, the enhanced planning system for Leksell Gamma Knife Perfexion also is boosting the efficiency of Karolinska's radiosurgery practice.

"Planning is a lot easier, more intuitive and very user friendly," Dr. Dodoo notes. "We can visualize the isodose lines simultaneously as we trace them and the dynamic shaping makes dose planning much simpler. It really has changed our approach."

The sophisticated automation that Perfexion brings to the clinic has transformed radiosurgery from a hands-on, technical procedure to one in which enhancing dose plans is the key objective, he adds. "Perfexion has allowed us to shift the focus from the technical, time-consuming part of treatment—changing collimators and adjusting table positions in half-millimeter steps—to creating the best dose plan for the patient."

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
2. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
3. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
4. Karolinska Development New Share Issue Completed - Raising 380 MSEK (36 MEUR)
5. Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
9. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
10. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
11. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- CSI Specialty Group (CSI) expanded its specialty pharmacy ... Pharmacy Podcast. A free, weekly show, the Specialty Pharmacy ... discussion and context amongst specialty pharmacy peers and professionals. ... The Specialty Pharmacy Podcast, hosted by industry leader ... DiMascio, CHE, CMCE, CPC, is available for streaming and/or ...
(Date:2/10/2016)... and SAN DIEGO , Feb. 10, ... global leader in viral gene therapy manufacturing, and Renova™ ... congestive heart failure and other chronic diseases, have entered ... manufacturing process and produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product ... --> --> This relationship ...
(Date:2/10/2016)... -- Urologix, the market leader for in-office minimally invasive ... (BPH), announces new private ownership and is operating as ... industry veteran of more than 20 years, has been ... Plymouth, Minn. The company,s two ... RF Therapy, will continue to be broadly available and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Sherly Sulaiman, certified clinical hypnotherapist and ... sessions to help Los Angeles-area actors cope with rejection, improve their auditions, and ... as “Mindfulness for Actors and Artists,” has been featured in Daily Actor ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO ... new 2.0 version at the International Roofing Expo in Orlando, Florida on February ... world's most advanced weather technology in the hands of consumers, roofing contractors, manufacturers ...
(Date:2/10/2016)... TX (PRWEB) , ... February 10, 2016 , ... ... commencement of a master charity program created to assist the local community. Pledging ... with community leaders and nonprofit organizations in the area. Their goal is to ...
(Date:2/10/2016)... ... 10, 2016 , ... Ongoing news of the ravages of traumatic brain injury ... a survey that takes a closer look at cases of TBI being managed by ... of TBI among the aging population, and identifies the challenges associated with their care. ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
Breaking Medicine News(10 mins):